Clene Inc. (CLNN) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
16/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinCLNN / S&P 24.95% / 15.20% |
LoseCLNN / S&P -31.12% / 15.00% |
LoseCLNN / S&P CLNN unavailable / 50.40% |
| 2026-Q10/3 |
LoseCLNN / S&P -16.01% / -4.33% |
LoseCLNN / S&P -61.71% / 11.30% |
LoseCLNN / S&P CLNN unavailable / 27.70% |
| 2025-Q40/3 |
LoseCLNN / S&P -2.65% / 2.65% |
LoseCLNN / S&P -41.52% / 9.00% |
LoseCLNN / S&P CLNN unavailable / 13.40% |
| 2025-Q31/3 |
WinCLNN / S&P 54.22% / 8.12% |
LoseCLNN / S&P -49.17% / 4.61% |
LoseCLNN / S&P CLNN unavailable / 13.45% |
| 2025-Q21/3 |
WinCLNN / S&P 26.95% / 10.94% |
LoseCLNN / S&P -35.29% / 4.83% |
LoseCLNN / S&P CLNN unavailable / 10.63% |
| 2025-Q10/3 |
LoseCLNN / S&P -42.00% / -4.27% |
LoseCLNN / S&P -43.55% / 4.98% |
LoseCLNN / S&P CLNN unavailable / 10.57% |
| 2024-Q41/3 |
WinCLNN / S&P 15.69% / 2.41% |
LoseCLNN / S&P -47.71% / 5.25% |
LoseCLNN / S&P CLNN unavailable / 6.15% |
| 2024-Q30/3 |
LoseCLNN / S&P -36.25% / 5.89% |
LoseCLNN / S&P -41.36% / 5.89% |
LoseCLNN / S&P CLNN unavailable / 6.11% |
| 2024-Q20/3 |
LoseCLNN / S&P -16.28% / 4.28% |
LoseCLNN / S&P -43.62% / 5.38% |
LoseCLNN / S&P CLNN unavailable / 5.12% |
| 2024-Q12/3 |
WinCLNN / S&P 43.33% / 10.56% |
WinCLNN / S&P 12.73% / 5.71% |
LoseCLNN / S&P CLNN unavailable / 5.59% |
| 2023-Q41/3 |
LoseCLNN / S&P -40.00% / 11.69% |
WinCLNN / S&P 38.27% / 6.81% |
LoseCLNN / S&P CLNN unavailable / 7.78% |
| 2023-Q31/3 |
LoseCLNN / S&P -43.18% / -3.27% |
WinCLNN / S&P 63.93% / 7.52% |
LoseCLNN / S&P CLNN unavailable / -5.03% |
| 2023-Q21/3 |
LoseCLNN / S&P -22.12% / 8.74% |
WinCLNN / S&P 109.63% / 9.50% |
LoseCLNN / S&P CLNN unavailable / -8.57% |
| 2023-Q11/3 |
WinCLNN / S&P 13.00% / 7.50% |
LoseCLNN / S&P 1.85% / 10.77% |
LoseCLNN / S&P CLNN unavailable / -15.69% |
| 2022-Q40/3 |
LoseCLNN / S&P -64.29% / 7.56% |
LoseCLNN / S&P -34.58% / 11.88% |
LoseCLNN / S&P CLNN unavailable / -17.99% |
| 2022-Q31/3 |
WinCLNN / S&P 11.11% / -4.88% |
LoseCLNN / S&P -20.80% / 13.47% |
LoseCLNN / S&P CLNN unavailable / -1.41% |
| 2022-Q20/3 |
LoseCLNN / S&P -36.04% / -16.10% |
LoseCLNN / S&P -30.87% / 13.71% |
LoseCLNN / S&P CLNN unavailable / 11.04% |
| 2022-Q12/3 |
WinCLNN / S&P -3.90% / -4.60% |
WinCLNN / S&P 54.73% / 15.97% |
LoseCLNN / S&P CLNN unavailable / 42.23% |
| 2021-Q41/3 |
LoseCLNN / S&P -39.97% / 11.03% |
WinCLNN / S&P 250.97% / 15.00% |
LoseCLNN / S&P CLNN unavailable / 96.40% |
| 2021-Q30/3 |
LoseCLNN / S&P -39.23% / 0.58% |
LoseCLNN / S&P CLNN unavailable / 10.77% |
LoseCLNN / S&P CLNN unavailable / 69.42% |
| 2021-Q20/3 |
LoseCLNN / S&P -12.05% / 8.55% |
LoseCLNN / S&P CLNN unavailable / 6.58% |
LoseCLNN / S&P CLNN unavailable / 51.81% |
| 2021-Q11/3 |
WinCLNN / S&P 18.11% / 6.17% |
LoseCLNN / S&P CLNN unavailable / -1.06% |
LoseCLNN / S&P CLNN unavailable / 7.39% |
| 2020-Q40/3 |
LoseCLNN / S&P -0.28% / 12.15% |
LoseCLNN / S&P CLNN unavailable / -3.72% |
LoseCLNN / S&P CLNN unavailable / -33.42% |
| 2020-Q30/3 |
LoseCLNN / S&P 0.56% / 8.93% |
LoseCLNN / S&P CLNN unavailable / -2.04% |
LoseCLNN / S&P CLNN unavailable / -27.10% |
| 2020-Q20/3 |
LoseCLNN / S&P 2.76% / 20.54% |
LoseCLNN / S&P CLNN unavailable / -0.46% |
LoseCLNN / S&P CLNN unavailable / -27.11% |
| 2020-Q11/3 |
WinCLNN / S&P 0.19% / -19.60% |
LoseCLNN / S&P CLNN unavailable / 3.47% |
LoseCLNN / S&P CLNN unavailable / -14.75% |
| 2019-Q40/3 |
LoseCLNN / S&P 1.85% / 9.07% |
LoseCLNN / S&P CLNN unavailable / 5.36% |
LoseCLNN / S&P CLNN unavailable / 2.99% |
| 2019-Q30/3 |
LoseCLNN / S&P 0.88% / 1.70% |
LoseCLNN / S&P CLNN unavailable / 5.02% |
LoseCLNN / S&P CLNN unavailable / 0.21% |
| 2019-Q20/3 |
LoseCLNN / S&P 1.09% / 4.30% |
LoseCLNN / S&P CLNN unavailable / 6.64% |
LoseCLNN / S&P CLNN unavailable / 8.65% |
| 2019-Q10/3 |
LoseCLNN / S&P 1.92% / 13.65% |
LoseCLNN / S&P CLNN unavailable / 8.12% |
LoseCLNN / S&P CLNN unavailable / 14.29% |
| 2018-Q40/3 |
LoseCLNN / S&P CLNN unavailable / -13.52% |
LoseCLNN / S&P CLNN unavailable / 9.05% |
LoseCLNN / S&P CLNN unavailable / 18.23% |
| 2018-Q30/3 |
LoseCLNN / S&P CLNN unavailable / 7.71% |
LoseCLNN / S&P CLNN unavailable / 10.21% |
LoseCLNN / S&P CLNN unavailable / 19.06% |
| 2018-Q20/3 |
LoseCLNN / S&P CLNN unavailable / 3.43% |
LoseCLNN / S&P CLNN unavailable / 9.03% |
LoseCLNN / S&P CLNN unavailable / 14.46% |
| 2018-Q10/3 |
LoseCLNN / S&P CLNN unavailable / -0.76% |
LoseCLNN / S&P CLNN unavailable / 7.68% |
LoseCLNN / S&P CLNN unavailable / 12.46% |
| 2017-Q40/3 |
LoseCLNN / S&P CLNN unavailable / 6.64% |
LoseCLNN / S&P CLNN unavailable / 7.03% |
LoseCLNN / S&P CLNN unavailable / 13.82% |
| 2017-Q30/3 |
LoseCLNN / S&P CLNN unavailable / 4.48% |
LoseCLNN / S&P CLNN unavailable / 5.68% |
LoseCLNN / S&P CLNN unavailable / 17.57% |
| 2017-Q20/3 |
LoseCLNN / S&P CLNN unavailable / 3.09% |
LoseCLNN / S&P CLNN unavailable / 4.83% |
LoseCLNN / S&P CLNN unavailable / 17.74% |
| 2017-Q10/3 |
LoseCLNN / S&P CLNN unavailable / 6.07% |
LoseCLNN / S&P CLNN unavailable / 3.67% |
LoseCLNN / S&P CLNN unavailable / 13.32% |
| 2016-Q40/3 |
LoseCLNN / S&P CLNN unavailable / 3.82% |
LoseCLNN / S&P CLNN unavailable / 2.09% |
LoseCLNN / S&P CLNN unavailable / 7.05% |
| 2016-Q30/3 |
LoseCLNN / S&P CLNN unavailable / 3.85% |
LoseCLNN / S&P CLNN unavailable / 0.20% |
LoseCLNN / S&P CLNN unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CLNN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -15.98% | 20.78% |
| Annualized return | -15.98% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CLNN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.33% | 83.14% |
| Annualized return | -51.54% | 12.86% |
10Y · 2018-10-18 to 2026-08-27
| Metric | CLNN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.71% | 319.30% |
| Annualized return | -31.45% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |